TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options Under Clinical Evaluation
Source: Childhood Central Nervous System Atypical Teratoid/Rhabdoid Tumor Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: March 3, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Recurrent Childhood CNS Atypical Teratoid/Rhabdoid Tumor
Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children’s Oncology Group (COG), the Pediatric Brain Tumor Consortium, or other entities. Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.
Source links and citations
The following is an example of a national and/or institutional clinical trial that is currently being conducted:
PEPN2121 (NCT05286801) (Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1- or SMARCA4-Deficient Tumors): This study is evaluating the combination of a PD-L1 targeting antibody (atezolizumab) with a TIGIT targeting antibody (tiragolumab) for patients with SMARCB1- or SMARCA4-deficient tumors. Patients with AT/RT may be eligible for this study.
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Preserved source evidence · Not medical advice